Raymond James Financial Inc. Purchases Shares of 243,364 Haemonetics Co. (NYSE:HAE)

Raymond James Financial Inc. bought a new stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 243,364 shares of the medical instruments supplier's stock, valued at approximately $19,002,000. Raymond James Financial Inc. owned 0.48% of Haemonetics at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in HAE. Arizona State Retirement System increased its holdings in shares of Haemonetics by 1.2% in the 4th quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier's stock worth $1,160,000 after buying an additional 181 shares during the last quarter. Parkside Financial Bank & Trust grew its position in Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after acquiring an additional 240 shares in the last quarter. HighTower Advisors LLC raised its position in Haemonetics by 7.8% during the fourth quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock valued at $262,000 after purchasing an additional 244 shares during the period. Xponance Inc. lifted its stake in shares of Haemonetics by 5.9% in the 4th quarter. Xponance Inc. now owns 7,246 shares of the medical instruments supplier's stock valued at $566,000 after purchasing an additional 404 shares during the last quarter. Finally, Isthmus Partners LLC boosted its holdings in shares of Haemonetics by 1.1% in the 4th quarter. Isthmus Partners LLC now owns 40,220 shares of the medical instruments supplier's stock worth $3,140,000 after purchasing an additional 450 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Needham & Company LLC lowered their price target on Haemonetics from $108.00 to $104.00 and set a "buy" rating for the company in a research report on Tuesday, March 18th. Bank of America lowered shares of Haemonetics from a "neutral" rating to an "underperform" rating and lowered their target price for the stock from $95.00 to $68.00 in a report on Friday, February 7th. Raymond James reiterated a "strong-buy" rating and set a $115.00 price target (down from $120.00) on shares of Haemonetics in a report on Friday, February 7th. StockNews.com lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. Finally, Barrington Research cut their target price on Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $101.22.

Haemonetics Trading Down 0.2 %

Shares of NYSE HAE traded down $0.13 during trading hours on Friday, reaching $61.80. The stock had a trading volume of 53,138 shares, compared to its average volume of 688,678. Haemonetics Co. has a 52-week low of $55.30 and a 52-week high of $97.97. The firm has a market cap of $3.10 billion, a price-to-earnings ratio of 24.31, a P/E/G ratio of 1.11 and a beta of 0.41. The business's fifty day moving average price is $62.86 and its two-hundred day moving average price is $72.25. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Analysts expect that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.